Timing Better For Sprout’s Latest Shot At First Female Sex Desire Drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sprout’s flibanserin resubmission should have an easier time at FDA, as experts backed key aspects of trial design used in flibanserin studies and patients sought treatment options at last year’s workshop on female sexual dysfunction.